Buparlisib/Chemo Combo Misses OS Mark in PD-1–Treated Recurrent HNC

The combination of buparlisib and paclitaxel did not show an improvement in overall survival (OS) compared with paclitaxel alone in patients with PD-1/PD-L1–pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC),…